BUZZ-Black Diamond rises as lung cancer drug meets main goal
Shares of precision oncology firm Black Diamond Therapeuticsrise 3.8% to $3.58 premarketCo says its experimental cancer drug silevertinib met main goal with 60% tumor response and 86% brain response in 43 lung cancer patients with rare EGFR mutationsEGFR is a protein that helps cells grow; mutations can drive cancerSeparately, co says it plans to start a mid-stage trial of silevertinib in patients with glioblastoma, an aggressive form of brain cancer, in the first half of 2026Up to last close, stock up 61% YTD
Shares of precision oncology firm Black Diamond Therapeutics (BDTX.O) rise 3.8% to $3.58 premarket
Co says its experimental cancer drug silevertinib met main goal with 60% tumor response and 86% brain response in 43 lung cancer patients with rare EGFR mutations
EGFR is a protein that helps cells grow; mutations can drive cancer
Separately, co says it plans to start a mid-stage trial of silevertinib in patients with glioblastoma, an aggressive form of brain cancer, in the first half of 2026
Up to last close, stock up 61% YTD
